Products
Platform
Research
Market
Learn
IPO
Compare DSP Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 4.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.92 | 1.86 |
NAV | ₹39.51 | ₹40.22 |
Fund Started | 12 Nov 2018 | 25 Jun 2018 |
Fund Size | ₹3143.91 Cr | ₹6437.36 Cr |
Exit Load | Exit load of 0.50% if redeemed within 1 month. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
4.0
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
1.92
1.86
NAV
₹39.51
₹40.22
Fund Started
12 Nov 2018
25 Jun 2018
Fund Size
₹3143.91 Cr
₹6437.36 Cr
Exit Load
Exit load of 0.50% if redeemed within 1 month.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | -5.12% | 3.31% |
3 Year | 20.37% | 26.49% |
5 Year | 16.32% | 18.90% |
1 Year
-5.12%
3.31%
3 Year
20.37%
26.49%
5 Year
16.32%
18.90%
Holding Analysis
Equity | 97.91% | 97.10% |
Cash | 2.09% | 2.90% |
Equity
97.91%
97.10%
Cash
2.09%
2.90%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Cipla Ltd. | 8.55% |
Sun Pharmaceutical Industries Ltd. | 8.26% |
Cohance Lifesciences Ltd. | 7.11% |
Ipca Laboratories Ltd. | 6.86% |
Laurus Labs Ltd. | 6.73% |
Gland Pharma Ltd. | 5.65% |
Illumina Inc. (USA) | 5.59% |
Sai Life Sciences Ltd. | 5.23% |
Apollo Hospitals Enterprise Ltd. | 4.76% |
Globus Medical Inc | 4.58% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.88% |
Dr. Reddy's Laboratories Ltd. | 9.42% |
Divi's Laboratories Ltd. | 8.50% |
Aurobindo Pharma Ltd. | 7.62% |
Cipla Ltd. | 6.61% |
Lupin Ltd. | 5.40% |
Alkem Laboratories Ltd. | 3.98% |
Biocon Ltd. | 3.28% |
Mankind Pharma Ltd. | 2.79% |
Zydus Lifesciences Ltd. | 2.67% |
Fund Manager
Name | Jay Kothari | Dharmesh Kakkad |
Start Date | 07 Mar 2024 | 23 Feb 2021 |
Name
Jay Kothari
Dharmesh Kakkad
Start Date
07 Mar 2024
23 Feb 2021
About Fund
Description | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 12 Nov 2018 | 25 Jun 2018 |
Description
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
12 Nov 2018
25 Jun 2018